BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Di Costanzo GG, Tortora R. Intermediate hepatocellular carcinoma: How to choose the best treatment modality? World J Hepatol 2015; 7(9): 1184-1191 [PMID: 26019734 DOI: 10.4254/wjh.v7.i9.1184]
URL: https://www.wjgnet.com/1007-9327/full/v7/i9/1184.htm
Number Citing Articles
1
Peter R. Galle, Francesco Tovoli, Friedrich Foerster, Marcus A. Wörns, Alessandro Cucchetti, Luigi Bolondi. The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapyJournal of Hepatology 2017; 67(1): 173 doi: 10.1016/j.jhep.2017.03.007
2
Mutlay Sayan, Nikhil Yegya-Raman, Stephanie H. Greco, Bin Gui, Andrew Zhang, Anupama Chundury, Miral S. Grandhi, Howard S. Hochster, Timothy J. Kennedy, Russell C. Langan, Usha Malhotra, Vinod K. Rustgi, Mihir M. Shah, Kristen R. Spencer, Darren R. Carpizo, John L. Nosher, Salma K. Jabbour. Rethinking the Role of Radiation Therapy in the Treatment of Unresectable Hepatocellular Carcinoma: A Data Driven Treatment Algorithm for Optimizing OutcomesFrontiers in Oncology 2019; 9 doi: 10.3389/fonc.2019.00345
3
Hussam Hijazi, Marie-Pierre Campeau, David Roberge, David Donath, Real Lapointe, Franck Vandenbroucke-Menu, Daniel Taussky, Karim Boudam, Gabriel Chan, Alexis Bujold, Guila Delouya. Stereotactic Body Radiotherapy for Inoperable Liver Tumors: Results of a Single Institutional ExperienceCureus 2016;  doi: 10.7759/cureus.935
4
Lior Charach, Lior Zusmanovitch, Gideon Charach. Hepatocellular Carcinoma. Part 2: Clinical Presentation and DiagnosisEMJ Hepatology 2017; : 81 doi: 10.33590/emjhepatol/10311703
5
Neal Bhutiani, Prejesh Philips, Charles R. Scoggins, Kelly M. McMasters, Melissa H. Potts, Robert C.G. Martin. Evaluation of tolerability and efficacy of irreversible electroporation (IRE) in treatment of Child-Pugh B (7/8) hepatocellular carcinoma (HCC)HPB 2016; 18(7): 593 doi: 10.1016/j.hpb.2016.03.609
6
Masatoshi Kudo. Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination TherapyCancers 2021; 13(21): 5475 doi: 10.3390/cancers13215475
7
Xi-Zhen Chen, Wei Kevin Zhang, He-Bin Tang, Xiao-Jun Li, Gui-Hua Tian, Hong-Cai Shang, Yu-Sang Li. The Ethanol Supernatant Extracts of Liushenwan Could Alleviate Nanodiethylnitrosamine-Induced Liver Cancer in MiceCanadian Journal of Gastroenterology and Hepatology 2018; 2018: 1 doi: 10.1155/2018/6934809
8
Eric A. Wang, Jeff P. Stein, Ross J. Bellavia, Scott R. Broadwell. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheresInternational Journal of Clinical Practice 2017; 71(11): e12972 doi: 10.1111/ijcp.12972
9
Qunfang Zhou, Fei Tuo, Ruixia Li, Xiaohui Wang, Juncheng Wang, Zhimei Huang, Minshan Chen, Jinhua Huang. Transarterial Chemoembolization Combined With Hepatectomy for the Treatment of Intermediate-Stage Hepatocellular CarcinomaFrontiers in Oncology 2020; 10 doi: 10.3389/fonc.2020.578763
10
Qizheng Dai, Bo Cao, Shiqing Zhao, Aili Zhang. Synergetic Thermal Therapy for Cancer: State-of-the-Art and the FutureBioengineering 2022; 9(9): 474 doi: 10.3390/bioengineering9090474
11
Bruna Scaggiante, Rosella Farra, Barbara Dapas, Gabriele Baj, Gabriele Pozzato, Mario Grassi, Fabrizio Zanconati, Gabriele Grassi. Aptamer targeting of the elongation factor 1A impairs hepatocarcinoma cells viability and potentiates bortezomib and idarubicin effectsInternational Journal of Pharmaceutics 2016; 506(1-2): 268 doi: 10.1016/j.ijpharm.2016.04.031
12
Experimental and Clinical Transplantation 2017; 15(Suppl 2) doi: 10.6002/ect.TOND16.L8
13
Matteo Renzulli, Francesco Tovoli, Alfredo Clemente, Anna Maria Ierardi, Irene Pettinari, Giuliano Peta, Giovanni Marasco, Davide Festi, Fabio Piscaglia, Salvatore Cappabianca, Gianpaolo Carrafiello, Rita Golfieri. Ablation for hepatocellular carcinoma: beyond the standard indicationsMedical Oncology 2020; 37(4) doi: 10.1007/s12032-020-01348-y
14
Jason K. Wong, Howard J. Lim, Vincent C. Tam, Kelly W. Burak, Laura A. Dawson, Prosanto Chaudhury, Robert J. Abraham, Brandon M. Meyers, Gonzalo Sapisochin, David Valenti, Setareh Samimi, Ravi Ramjeesingh, Amol Mujoomdar, Ilidio Martins, Elijah Dixon, Maja Segedi, David M. Liu. Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in CanadaCancer Treatment Reviews 2023; 115: 102526 doi: 10.1016/j.ctrv.2023.102526
15
Masatoshi Kudo, Richard S. Finn, Manabu Morimoto, Kun-Ming Rau, Masafumi Ikeda, Chia-Jui Yen, Peter R. Galle, Josep M. Llovet, Bruno Daniele, Ho Yeong Lim, David W. McIlwain, Reigetsu Yoshikawa, Kenichi Nakamura, Kun Liang, Chunxiao Wang, Paolo Abada, Ryan C. Widau, Andrew X. Zhu. Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2)Liver Cancer 2021; 10(5): 451 doi: 10.1159/000516605
16
Jian-Jun Gao, Zhen-Yan Shi, Ju-Feng Xia, Yoshinori Inagaki, Wei Tang. Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinomaWorld Journal of Gastroenterology 2015; 21(42): 12059-12070 doi: 10.3748/wjg.v21.i42.12059
17
V. V. Breder, M. U. Pitkevich, E. R. Virshke, L. A. Kostyakova, I. A. Dzhanyan, K. K. Laktionov. BCLC-B hepatocellular carcinoma treatment or when should the systemic therapy be startedMedical Council 2018; (10): 27 doi: 10.21518/2079-701X-2018-10-27-32